Sanofi India Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/x1ihyjmg7a7pmlikdwlifefc.pdf

Key Takeaways


Lantus NLEM: The Price-Cut Mechanism

Vaibhav Karandikar: “In case there is a drop in profitability below the arm's length, this would be compensated by the group. Effectively, it means the purchase price of the product will drop and the discussion will be taken with the group companies for that.”

Diabetes Portfolio: Toujeo Rises, Lantus Steps Back

Rodolfo Hrosz: “Lantus performance this year was negatively impacted by a high focus of the organization behind the acceleration of Toujeo. Toujeo grew very strongly. And part of that growth came out of Lantus.”

Q4 FY22 Performance & the New Baseline

Vaibhav Karandikar: “Q4 '22 is the first quarter where the compare -- it's largely comparable quarter. And it can -- from a comparison and a growth perspective, it is easy for us to monitor Sanofi's performance quarter-on-quarter from now on because the exceptional impact largely diminishes going forward.”

The “India for India” Strategic Plan

Rodolfo Hrosz: “We called it India for India, Sanofi's India for India plan.”

Innovation & Local Manufacturing

Rodolfo Hrosz: “The plan is to bring innovation to the market. It will happen in the coming quarters and years. But it will happen in the coming years, let's put it this way. But it could not have happened immediately, in consumer goods, you would be able to decide to innovate and tomorrow already in our industry, it takes a little longer.”

Guidance & Commitments

CommitmentSpecificsTimeline
Operating efficienciesResource mobilization and deployment efficiencies to continue being visibleNext quarters (from Q1 FY24 onward)
Clexane normalizationMore normalized growth expected as COVID impact is out of the questionFrom FY23 onward
Lantus NLEM bottom-line protectionBottom-line impact limited; arm’s length mechanism will adjust purchase price from the groupUpon final price notification (date pending)
WPI price increaseNext WPI increase expected; company hopeful government notification will reflect index numbersApril 2023
Innovation launchesInnovation to be brought to market under the “India for India” planComing quarters and years
Integrated ESG reportingFirst integrated report with ESG figures to be disclosedUpcoming annual report

Key Metrics

MetricQ3 FY23
Revenue (retail business, comparable)+3.7% YoY, excluding Nutraceuticals, Soframycin, and COVID impact; published de-growth of 2%
Revenue (retail business, published)–2% YoY
Export growth+26% YoY
Profit before tax (comparable)+6% YoY, excluding exceptional items
Profit before tax (published)–5% YoY
Profit before tax margin28% of sales, up from 22% in FY17
NLEM exposure15% to 16% of sales; expected to rise to 40% if Lantus is included
Lantus draft price cut~25% average reduction across SKUs, per draft notification
Cardace expected price reduction~14% for plain tablets under NLEM
Diabetes patient coverageAbove 7 lakh patients in 2021, up from ~6.5 lakh in 2020
Vitamin D3 market share5%, in a market of ₹800 cr growing at 3%
Retail business CAGR (pure)7.2% over the period shown
Full portfolio CAGR (incl. divested)~5% over the period shown
Diabetes business coverage increase150–200 people reallocated to strengthen diabetes coverage